Cargando…
Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis
BACKGROUND: Because of the heterogeneity of hepatitis C virus (HCV) distribution of different genotypes, large-scale clinical trials on direct-acting antiviral (DAA) mainly included patients with genotype 1 and genotype 3 infection. Data on the efficacy of direct-acting antiviral agents in patients...
Autores principales: | Luo, Aoran, Xu, Pan, Wang, Jin, Li, Zuli, Wang, Shunli, Jiang, Xiaoyan, Ren, Hong, Luo, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531202/ https://www.ncbi.nlm.nih.gov/pubmed/31096473 http://dx.doi.org/10.1097/MD.0000000000015626 |
Ejemplares similares
-
Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6
por: Due, Ong The, et al.
Publicado: (2019) -
Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection
por: Mei, Yong-yu, et al.
Publicado: (2020) -
Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016) -
Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019) -
Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
por: Li, Zhanyi, et al.
Publicado: (2017)